Origin & tradition
Originally derived from Galega officinalis (French lilac); now a first-line diabetes prescription drug.
Western tradition · Biguanide · prescription
Metformin 二甲双胍
The diabetes drug at the center of the longevity debate — and the TAME trial designed to test aging itself.
Why longevity buyers care
Key active: Metformin (biguanide).
Metformin activates AMPK and dampens hepatic glucose output; observational data hint at lower age-related disease in diabetics, and the landmark TAME trial is designed to test whether it slows aging endpoints in non-diabetics.
Evidence summary
What the research actually says
78Evidence confidence
Extensive human-trial evidence3,523 randomized controlled trials · 1,317 meta-analyses / systematic reviews
Large clinical use; longevity endpoint trial (TAME) pending
Metformin activates AMPK and dampens hepatic glucose output; observational data hint at lower age-related disease in diabetics, and the landmark TAME trial is designed to test whether it slows aging endpoints in non-diabetics.
3,064registered clinical trials reference this intervention
3selected from 279+ PubMed papers (longevity / aging angle)
Key active: Metformin (biguanide).
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-06-06. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Compare the evidence
How Metformin stacks up
Verified suppliers
No verified Metformin suppliers listed yet
Tell us what you need and we will source verified suppliers for you.